{"id":498782,"date":"2021-05-26T08:04:42","date_gmt":"2021-05-26T12:04:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/"},"modified":"2021-05-26T08:04:42","modified_gmt":"2021-05-26T12:04:42","slug":"foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/","title":{"rendered":"Foghorn Therapeutics to Present in Two Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., May  26, 2021  (GLOBE NEWSWIRE) &#8212; Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Adrian Gottschalk, President and Chief Executive Officer, will present at two upcoming investor conferences.<\/p>\n<p align=\"justify\">\n        <strong>Events:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Jefferies Virtual Healthcare Conference<\/strong><br \/>\n        <br \/>Format: Presentation and 1x1s<br \/>Tuesday, June 1, 2021<br \/>10:00am ET<\/p>\n<p align=\"justify\">\n        <strong>Goldman Sachs 42<\/strong><br \/>\n        <sup><br \/>\n          <strong>nd<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Healthcare Conference <\/strong><br \/>\n        <br \/>Format: Fireside Chat and 1x1s<br \/>Tuesday, June 8, 2021<br \/>8:00am ET<\/p>\n<p align=\"justify\">A live webcast of both presentations can be accessed under \u201cEvents &amp; Presentations\u201d in the Investors section of the Company\u2019s website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aYHpUeIwFWLF3BOp0TCTCT8vVMJ0GHRD219s4zkRqHpO-V7T_VrrqL6jjgmndg-6cH8aHWxXlV9LFSIKgbs6xw==\" rel=\"nofollow noopener\" target=\"_blank\">www.foghorntx.com<\/a>.<\/p>\n<p>\n        <strong>About Foghorn Therapeutics <\/strong>\n      <\/p>\n<p>Foghorn\u00ae Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control\u00ae platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.<\/p>\n<p>\n        <strong>Media Contact:<\/strong>\n      <\/p>\n<p>Fanny Cavali\u00e9, Foghorn Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UvP6syPUUrNz-smvuJay2NjoUAPfITMhseBCpTFThhRJBdinlsl5Lt6CVYcTLxSi5rKP7U5MBInCNcpMF5-cP4XtUz-7BVyZBW3uFPZ1Rm0=\" rel=\"nofollow noopener\" target=\"_blank\">fcavalie@foghorntx.com<\/a><\/p>\n<p>Gregory Kelley, Ogilvy<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L8FlZAyR8DoqMYfBJ1SX8vv4_HpdtB7syvVAx7S73KLEO8-HMSI6jWVk2wDRXMasn6NtPyVpSYmrohLLE3JnLZnxjeAIBSf-zB-xEJzEVpM=\" rel=\"nofollow noopener\" target=\"_blank\">gregory.kelley@ogilvy.com<\/a><\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong>\n      <\/p>\n<p>Allan Reine, Foghorn Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CTFpWeP-Ch5rJK50O6kJV7q92yU4j1wndN6xXXJmnl8XuGoNVg5Y1S3ePBhKH8xbNZ8pP5ZLca2ujq9ZCLqddjo6UU4axDT13QgOOWHQJAQ=\" rel=\"nofollow noopener\" target=\"_blank\">areine@foghorntx.com<\/a><\/p>\n<p>Hans Vitzthum, LifeSci Advisors<br \/>617-430-7578<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UUCTCt-0TQHXjNrr-oprGRg-Pec29DUXigREjBgtuI3hlrQkwFTHS0T9CZxwgUKq_CMBg7qzJiyGwOl_cQCkA-9rBykID39l6WbKegfWqxg=\" rel=\"nofollow noopener\" target=\"_blank\">hans@lifesciadvisors.com<\/a><\/u><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MzQ4OCM0MjAzMDY1IzIyMDI4NjI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/5de34db7-58e3-4d08-a150-3dcd0062b942\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) &#8212; Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Adrian Gottschalk, President and Chief Executive Officer, will present at two upcoming investor conferences. Events: Jefferies Virtual Healthcare Conference Format: Presentation and 1x1sTuesday, June 1, 202110:00am ET Goldman Sachs 42 nd Annual Healthcare Conference Format: Fireside Chat and 1x1sTuesday, June 8, 20218:00am ET A live webcast of both presentations can be accessed under \u201cEvents &amp; Presentations\u201d in the Investors section of the Company\u2019s website, www.foghorntx.com. About Foghorn Therapeutics Foghorn\u00ae Therapeutics is discovering and developing a novel class of medicines targeting genetically determined &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Foghorn Therapeutics to Present in Two Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-498782","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Foghorn Therapeutics to Present in Two Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Foghorn Therapeutics to Present in Two Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) &#8212; Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Adrian Gottschalk, President and Chief Executive Officer, will present at two upcoming investor conferences. Events: Jefferies Virtual Healthcare Conference Format: Presentation and 1x1sTuesday, June 1, 202110:00am ET Goldman Sachs 42 nd Annual Healthcare Conference Format: Fireside Chat and 1x1sTuesday, June 8, 20218:00am ET A live webcast of both presentations can be accessed under \u201cEvents &amp; Presentations\u201d in the Investors section of the Company\u2019s website, www.foghorntx.com. About Foghorn Therapeutics Foghorn\u00ae Therapeutics is discovering and developing a novel class of medicines targeting genetically determined &hellip; Continue reading &quot;Foghorn Therapeutics to Present in Two Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-26T12:04:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MzQ4OCM0MjAzMDY1IzIyMDI4NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Foghorn Therapeutics to Present in Two Upcoming Investor Conferences\",\"datePublished\":\"2021-05-26T12:04:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\\\/\"},\"wordCount\":202,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0MzQ4OCM0MjAzMDY1IzIyMDI4NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\\\/\",\"name\":\"Foghorn Therapeutics to Present in Two Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0MzQ4OCM0MjAzMDY1IzIyMDI4NjI=\",\"datePublished\":\"2021-05-26T12:04:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0MzQ4OCM0MjAzMDY1IzIyMDI4NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0MzQ4OCM0MjAzMDY1IzIyMDI4NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Foghorn Therapeutics to Present in Two Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Foghorn Therapeutics to Present in Two Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Foghorn Therapeutics to Present in Two Upcoming Investor Conferences - Market Newsdesk","og_description":"CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) &#8212; Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Adrian Gottschalk, President and Chief Executive Officer, will present at two upcoming investor conferences. Events: Jefferies Virtual Healthcare Conference Format: Presentation and 1x1sTuesday, June 1, 202110:00am ET Goldman Sachs 42 nd Annual Healthcare Conference Format: Fireside Chat and 1x1sTuesday, June 8, 20218:00am ET A live webcast of both presentations can be accessed under \u201cEvents &amp; Presentations\u201d in the Investors section of the Company\u2019s website, www.foghorntx.com. About Foghorn Therapeutics Foghorn\u00ae Therapeutics is discovering and developing a novel class of medicines targeting genetically determined &hellip; Continue reading \"Foghorn Therapeutics to Present in Two Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-26T12:04:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MzQ4OCM0MjAzMDY1IzIyMDI4NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Foghorn Therapeutics to Present in Two Upcoming Investor Conferences","datePublished":"2021-05-26T12:04:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/"},"wordCount":202,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MzQ4OCM0MjAzMDY1IzIyMDI4NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/","name":"Foghorn Therapeutics to Present in Two Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MzQ4OCM0MjAzMDY1IzIyMDI4NjI=","datePublished":"2021-05-26T12:04:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MzQ4OCM0MjAzMDY1IzIyMDI4NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MzQ4OCM0MjAzMDY1IzIyMDI4NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-in-two-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Foghorn Therapeutics to Present in Two Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/498782","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=498782"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/498782\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=498782"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=498782"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=498782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}